Patents Assigned to INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)
  • Patent number: 11905253
    Abstract: The present invention relates the field of reducing CD95-mediated cell motility in a subject, in particular for their use in the reduction of CD-95 mediated cancer cell motility, the reduction of CD95-mediated lymphocyte motility and/or B cell maturation, or the treatment of B-cell tumors, in a subject. The inventors identified a novel family of compounds having the ability to disrupt CD95/PLC?1 interaction and to neutralize the CD95-mediated calcium signaling pathway and cell migration in human peripheral blood lymphocytes (PBLs) and Th17 cells.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: February 20, 2024
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE RENNES 1, CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX, INSTITUT BERGONIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE BORDEAUX
    Inventors: Pierre Vacher, Patrick Legembre, Mickael Jean, Patrick Blanco, Pierre Van De Weghe
  • Publication number: 20240053345
    Abstract: The present invention relates to a polypeptide X1X2-RK-X3X4-KK-X5X6X7X8X9X10-KR-X11X12 SEQ ID NO: 1 able to bind selectively to cells expressing proteoglycans comprising glycosaminoglycans as heparin or heparan sulfate. The linkage of said polypeptide to an internalization peptide enables the polypeptide to be internalized. The present invention further relates to a conjugated polypeptide comprising said polypeptide and a biomarker, to a cell penetrating polypeptide comprising said polypeptide, optionally a linker and a cell internalization peptide and a chimeric polypeptide comprising said cell penetrating polypeptide and one or more biological cargos.
    Type: Application
    Filed: December 17, 2020
    Publication date: February 15, 2024
    Applicants: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ECOLE NORMALE SUPERIEURE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), COLLEGE DE FRANCE
    Inventors: Sandrine Sagan, Alain Joliot, Astrid Walrant, Ludovic Carlier, Sébastien Cardon
  • Patent number: 11883398
    Abstract: The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.
    Type: Grant
    Filed: December 15, 2021
    Date of Patent: January 30, 2024
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Rosa Barreira Da Silva, Matthew Albert
  • Publication number: 20240010739
    Abstract: SARS-CoV-2 vaccines will be essential to reduce morbidity and mortality. The inventors produced an antibody that is directed against a surface antigen (i.e. CD40) of an antigen presenting cell (i.e. dendritic cell) wherein the heavy chain was conjugated to the receptor-binding domain of the Sars-Cov-2 spike protein for its use as vaccine. In particular, the inventors show that said vaccine induces circulating Ab-secreting hu-B cells, elicits S-specific IgG+ hu-B cells, elicits the expansion of central memory CD4+ hu-T cells and the emergence of effector memory CD4+ T cells, elicits the expansion of central memory CD8+ hu-T cells at and the emergence of effector memory CD8+ T cells at and finally induces Stem-cell like memory hu-CD8+ T cells.
    Type: Application
    Filed: November 10, 2021
    Publication date: January 11, 2024
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hopitaux de Paris (APHP), Baylor Research Institute, Universite Paris Est Creteil Val De Marne
    Inventors: Yves LEVY, Gérard ZURAWSKI, Mireille CENTLIVRE, Sandra ZURAWSKI, Véronique GODOT
  • Patent number: 11865185
    Abstract: The invention is directed to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L, wherein coupling of said ligand L is implemented through a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety. The present invention further relates to a method for chemically coupling an Adeno-Associated Virus (AAV) vector particle with at least one ligand L and to a Recombinant Adeno-Associated Virus (rAAV) vector particle obtained by said method as well as a pharmaceutical composition comprising it and their corresponding medical use.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: January 9, 2024
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), NANTES UNIVERSITE, CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
    Inventors: Mathieu Mevel, David Deniaud, Eduard Ayuso
  • Patent number: 11852704
    Abstract: The present disclosure is directed to a motor for a magnetic resonance (MR) tomography room, to a patient table for the MR room, to a MR elastography device, and to a MR tomography device. A MR tomography device for a MR elastography imaging protocol is arranged within the MR tomography room, and includes a rotational drive for supplying rotational energy to power a MR elastography transducer usable during the MR elastography imaging protocol, and a support structure. The rotational drive comprises a terminal for connecting the MR elastography transducer to the rotational drive, and a bearing means configured such that the position of the terminal relative to the support structure is adaptable along a trajectory predetermined by the bearing means. The rotational drive is mounted to the support structure via the bearing means.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: December 26, 2023
    Assignees: Siemens Healthcare GmbH, Centre National de la Recherche Scientifique (CNRS), Institut National de La Sante et de la Recherche Medicale (INSERM), King's College London, Department of Health and Human Services, UNIV PARIS XIII PARIS-NORD VILLETANEUSE, Universite de Paris
    Inventors: Giacomo Annio, Verena Muller-Reinwald, Ralph Sinkus, Omar Darwish, Wilfried Schnell, Tamara Elisabeth Falkner, Ahmed M. Gharib
  • Publication number: 20230382991
    Abstract: An antagonist antibody, or an antigen binding fragment thereof, binds both to human and macaque LILRB1 and/or LILRB2, and has diagnostic and therapeutic uses.
    Type: Application
    Filed: October 12, 2021
    Publication date: November 30, 2023
    Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, UNIVERSITE PARIS SACLAY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Benoit FAVIER, Sixtine COINDRE, Anne WIJKHUISEN, Stéphanie SIMON, Roger LE GRAND, Olivier LAMBOTTE
  • Patent number: 11827637
    Abstract: The present invention concerns a compound of formula (I): or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity, in particular ERK2 activity.
    Type: Grant
    Filed: January 13, 2023
    Date of Patent: November 28, 2023
    Assignees: AGV Discovery, Institut National de la Sante et de la Recherche Medicale (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Université De Montpellier
    Inventors: Cédric Bories, Loïc Mathieu, Jean-François Guichou, Muriel Gelin, Aurélien Biechy
  • Patent number: 11827747
    Abstract: The present invention concerns a polymer comprising repetitive units having the following formula (I) wherein R1 is H or Me; L is a linker; R2 is the side chain of an ?-amino acid being other than arginine; m is 0 or an integer comprised from 1 to 10; n is an integer comprised from 1 to 10; and X— is a counterion.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: November 28, 2023
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITÉ DE STRASBOURG
    Inventors: Fouzia Boulmedais, Delphine Chan-Seng, Nicolas Zydziak, Philippe Lavalle
  • Patent number: 11819492
    Abstract: The present invention relates to a compound of the following general formula (I): or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.
    Type: Grant
    Filed: December 10, 2021
    Date of Patent: November 21, 2023
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Sorbonne Universite, Universite de Poitiers, Centre Hospitalier Universitaire de Poitiers
    Inventors: Stéphane Bach, Marie-Thérèse Dimanche-Boitrel, Claire Delehouze, Thierry Hauet
  • Patent number: 11814685
    Abstract: This invention relates to a method for diagnosing and/or prognosticating HER2-dependent cancer in a subject, comprising a) measuring the amount of one or more miRNA selected from the group consisting of miRNA 429-3p, miRNA 29c-3p, miRNA 29a-3p, miRNA 29b-3p, miRNA 200a-3p, miRNA 200b-3p, miRNA 200c-3p, miRNA 141-3p, miRNA 15a-5p, miRNA 15b-5p, miRNA 16-5p, miRNA 424-5p, miRNA 497-5p, miRNA 615-3p, miRNA 451a-3p and miRNA 542-5p in a sample from the subject; b) comparing the amount of one or more miRNA measured in step a) to a reference value; c) finding a deviation or no deviation of the amount of one or more miRNA measured in step a) from the reference value; and d) attributing said finding of deviation or no deviation to a particular diagnosis and/or prognosis of HER2-dependent cancer in the subject.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: November 14, 2023
    Assignees: UNIVERSITÉ PARIS CITÉ, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)
    Inventors: Sandrine Bourdoulous, Anaïs Domingot, Camille Faure
  • Publication number: 20230348934
    Abstract: The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain. The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.
    Type: Application
    Filed: March 6, 2023
    Publication date: November 2, 2023
    Applicants: Ecole Normale Superieure de Lyon, Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1, Institut National de la Santé et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique
    Inventors: Caroline COSTA FEJOZ, Els Verhoeyen, François-Loîc Cosset, Ruben Bender, Christian Buchholz, Qi Zhou
  • Patent number: 11793865
    Abstract: A composition including a supernatant obtained from co-culture of phagocytes with apoptotic cells. The composition is obtained by a) providing phagocytes, b) providing apoptotic cells, c) optionally washing the cells from step a) and b), d) co-culturing the cells of step a) and b), and e) separating the supernatant from the cells. The composition may be used in preventing or treating a pathological immune response.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: October 24, 2023
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ETABLISSEMENT FRANCAIS DU SANG, UNIVERSITE DE FRANCHE-COMTE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE BESANCON
    Inventors: Sylvain Perruche, Philippe Saas, Francis Bonnefoy
  • Patent number: 11795144
    Abstract: The present invention concerns a compound having the following formula (I): wherein: A is in particular —N(R?a)—C(?O)—R, R?a being H or a (C1-C6)alkyl group, and R being preferably a group having the following formula (II): X is in particular chosen from the group consisting of: —SO2—N(R?b)—, R?b being H or a (C1-C6)alkyl group, —N(R?b)—SO2—, R?b being H or a (C1-C6)alkyl group, —CO—NH—, and —NH—CO—, for use for the treatment of cancers, such as metastatic cancers.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: October 24, 2023
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE NANTES, CHU NANTES
    Inventors: Vincent Sauzeau, Gervaise Loirand, Jacques Lebreton, Arnaud Tessier, Agnès Quemener
  • Publication number: 20230306731
    Abstract: Method for the prediction of labels associated with a digital image, comprising a prediction phase consisting of: supplying the image to a segmentation neural network configured to predict a classification of the pixels of the image into a first set of classes; and supplying at least part of this classification to a classification neural network configured to predict a set of labels for said image, based on the classification P of the pixels; said segmentation and classification neural networks being determined by a learning phase comprising, for each image of a training set, the first and second steps; and determining a location of the background of said image, based on the classification of the pixels, and optimizing the weights of the neural networks according to a set of cost functions configured, by iteration, to maximize the quality of the set of labels as a function of labels previously established and associated with the image, and to maximize the probability of not predicting any label for the bac
    Type: Application
    Filed: July 21, 2021
    Publication date: September 28, 2023
    Applicants: UNIVERSITE BRESTBRETAGNE OCCIDENTALE, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)
    Inventor: Gwenolé QUELLEC
  • Patent number: 11767333
    Abstract: The invention relates to 4-(1-hydroxy-3,4-dihydro-1H-benzo[c][1,2]oxaborinin-3-yl)benzimidamide derivatives and their use in treating diseases and conditions of the skin (for example, Netherton syndrome, rosacea, atopic dermatitis, psoriasis and itch) caused by abnormally high levels of protease activity (particularly of serine proteases such as kallikreins). In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: September 26, 2023
    Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: John Liddle, Ann Louise Walker, Gemma Victoria White, Alexis Denis, Nerina Dodic, Marie-Hélène Fouchet, Anne Bouillot
  • Publication number: 20230293478
    Abstract: The invention relates compound of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diastereoisomers thereof: wherein W, X, Y and Z are as defined, for use in the treatment of Acute Myeloid Leukemia (AML).
    Type: Application
    Filed: May 12, 2021
    Publication date: September 21, 2023
    Applicants: Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Curie, Peter MacCallum Cancer Institute
    Inventors: Raphaël RODRIGUEZ, Mark DAWSON, Sylvain GARCIAZ, Tatiana CANEQUE COBO
  • Publication number: 20230293586
    Abstract: The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydrocarbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.
    Type: Application
    Filed: April 6, 2023
    Publication date: September 21, 2023
    Applicants: Assistance Publique - Hopitaux de Paris, Fondation Imagine - Institut des Maladies Génétiques, Université Paris Cité, Institut National de la Santé et de la Recherche Médicale (INSERM)
    Inventors: Isabelle ANDRÉ, Marina CAVAZZANA, Kuiying MA, John TCHEN, Tayebeh-Shabi SOHEILI, Ranjita Devi MOIRANGTHEM
  • Publication number: 20230285381
    Abstract: The present invention relates to compounds of formula (I); for use as peripheral NMDA receptor antagonists.
    Type: Application
    Filed: April 6, 2023
    Publication date: September 14, 2023
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ PARIS-SACLAY, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (APHP), HOPITAL MARIE LANNELONGUE
    Inventors: Sylvia COHEN-KAMINSKY, Marc HUMBERT, Sebastien DUMAS, Gilles BRU-MERCIER, Samir MESSAOUDI, Jean-Daniel BRION, Mouad ALAMI, Gilles GALVANI
  • Patent number: 11744863
    Abstract: Process for preparing a heat-treated pooled human platelet lysate, said process comprising the steps of: a) Providing a pooled human platelet lysate (p HPL), b) Heat-treating the pooled human platelet lysate at a temperature of 50° C. to 70° C. during 20 to 40 minutes, c) Purifying the heat-treated pooled human platelet lysate of step b).
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: September 5, 2023
    Assignees: Centre Hospitalier Regional et Universitaire De Lille (CHRU), UNIVERSITE DE LILLE 2 DROIT ET SANTE, UNIVERSITE DU LITTORAL COTE D'OPALE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), TAIPEI MEDICAL UNIVERSITY
    Inventors: David Devos, Thierry Burnouf, Jean-christophe Devedjian, Ming-Li Chou, Flore Gouel